Thursday, April 3rd, 2025

OneApex Limited Announces 9.5% Dividend Payout for Shareholders in February 2025








OneApex Declares Generous Final and Special Dividends, Shareholders Take Note

OneApex Declares Generous Final and Special Dividends, Shareholders Take Note

OneApex Limited, a Singapore-based company, has announced a substantial payout for its shareholders, comprising both a final tax-exempt (one-tier) dividend and a special tax-exempt (one-tier) dividend. This announcement, approved during the company’s Annual General Meeting on January 27, 2025, has the potential to impact the company’s share value, making it a development to watch closely for investors.

Key Details on the Dividends

  • Final Dividend: 1.0 Singapore cent per ordinary share.
  • Special Dividend: 8.5 Singapore cents per ordinary share.
  • Total Dividend Payout: 9.5 Singapore cents per share.

This generous payout, particularly the special dividend, underscores OneApex’s strong financial performance for the fiscal year ended September 30, 2024. Such announcements often signal confidence in the company’s financial health and may positively influence investor sentiment.

Important Dates for Shareholders

  • Books Closure Date: February 6, 2025, at 5:00 p.m. Shareholders must ensure their shares are registered with the company’s Share Registrar, Tricor Barbinder Share Registration Services, by this deadline.
  • Payment Date: February 14, 2025. Shareholders whose securities accounts with The Central Depository (Pte) Limited are credited as of the books closure date will receive the dividends.

Shareholders are advised to verify their holdings and ensure timely registration to secure their entitlement to the dividends. This is a time-sensitive process, and missing the cut-off date may result in ineligibility for the payouts.

Potential Share Price Impact

The combined dividend payout of 9.5 cents per share is significant and could attract interest from dividend-focused investors. The announcement may prompt increased trading activity in the company’s shares leading up to the books closure date, potentially impacting the share price. Investors should carefully monitor market reactions and consider their investment strategies accordingly.

Corporate Governance and Compliance

This announcement was reviewed by OneApex’s sponsor, Novus Corporate Finance Pte. Ltd., in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (SGX-ST) Listing Manual Section B: Rules of Catalist. The SGX-ST has not examined or approved the announcement and assumes no responsibility for its content.

Contact Information

For further inquiries, shareholders can contact OneApex’s sponsor, Novus Corporate Finance Pte. Ltd. The key contact person is Mr. Andrew Leo, Chief Executive Officer, based at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987. He can be reached at +65 6950 2188.

By Order of the Board:
Tan Pei Hong, Alex
Chief Executive Officer and Executive Director
Dated: January 27, 2025

Disclaimer

This article is for informational purposes only and does not constitute financial advice. Readers should consult their financial advisor before making any investment decisions. The information provided is based on the announcement made by OneApex Limited and is accurate as of the publication date. Neither the author nor the publisher assumes any responsibility for actions taken based on this article.




View OneApex Historical chart here



Civmec Wins Major Shiploader Contract: A$90-100M Project Boost Amid FY25 Outlook Concerns

Major Project Win and Strong Outlook: Civmec’s \$100M Shiploader Contract Major Project Win and Strong Outlook: Civmec’s \$100M Shiploader Contract Civmec Limited (ASX:CVL, SGX:P9D) has announced a significant milestone in their business activities with...

Clearbridge Health Announces Key Dates for 1.28 Billion Share Rights Issue

Clearbridge Health’s Strategic Rights Issue: A Closer Look at Shareholder Opportunities Clearbridge Health’s Strategic Rights Issue: A Closer Look at Shareholder Opportunities Clearbridge Health Limited has announced a proposed renounceable non-underwritten rights issue, aiming...

VICOM’s Q3 2024 Results: OBU Project Boosts Revenue Amidst Rising Costs and Competition

VICOM Ltd Reports Strong Q3 2024 Performance Amid Competitive Pressures VICOM Ltd Reports Strong Q3 2024 Performance Amid Competitive Pressures VICOM Ltd has announced its financial results for the third quarter of 2024, showcasing...